Apellis Presents Phase 3 Functional Analyses of SYFVORE™ (pegcetacoplan injection) for Geographic Atrophy
April 23, 2023
WALTHAM, Mass., (GLOBE NEWSWIRE) — Apellis Pharmaceuticals, Inc. (Nasdaq: APLS), a global biopharmaceutical company and leader in complement, today announced post hoc analyses from the